Funding Round
Omniscient Neurotechnology closes A$50M Series C for AI neurosurgery planning platform
AFR3/15/2026·03/15/26🌐 Asia
Summary
Sydney-based Omniscient Neurotechnology secured A$50M Series C led by General Atlantic, with Blackbird Ventures and Main Sequence Ventures. The company's qEEG connectome-based surgical planning platform is now used at 80 hospitals globally. The round will fund US commercial scale-up and a pivotal study for DBS planning in Parkinson's disease.
Why it matters
General Atlantic's entry into Omniscient signals the platform has crossed from research tool to commercial medical device territory. Their 80-hospital footprint and General Atlantic's commercial scaling expertise suggest a US IPO or strategic acquisition within 3-4 years.
#AI#AI Diagnostics#Australia#Industry#Neuroimaging#Neurostimulation#Venture Capital
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trialAlready a member? Sign in